Inhalational Alzheimer's disease: an unrecognized—and treatable—epidemic

Bredesen, Dale E.

doi:10.18632/aging.100896

Cited by 28 publications

(17 citation statements)

References 12 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Social as well as economical costs of AD prevention and cure require improved methods of diagnosis and treatment. There are currently no effective treatment for AD [40], no biomarkers for early diagnosis of AD and the pathogenesis of AD is uncertain even now [22,41]. Therefore, it is vital to expand our knowledge of AD pathogenic mechanisms or we will nearly fail to develop efficient therapies for AD.…”

Section: Authors Contributionmentioning

confidence: 99%

Lack of association between MTHFR A1298C variant and Alzheimer’s disease: evidence from a systematic review and cumulative meta-analysis

Liu¹,

Wu²,

Liu³

et al. 2017

Neurological Research

View full text Add to dashboard Buy / Rent full text

Objectives: Previous studies have investigated the association between MTHFR A1298C (rs1801131) polymorphism and susceptibility to Alzheimer's disease (AD). Nevertheless, an ultimate conclusion remains obscure. We then executed this meta-analysis to estimate this association more precisely. Methods: Related studies were systematically searched on PubMed, Embase, China National Knowledge Infrastructure, Google scholar, and AlzGene databases. The association was evaluated by reviewing the odds ratios (ORs) with corresponding 95% confidence intervals (CIs). Publication bias, sensitivity analysis, and cumulative meta-analysis were performed to help draw a more definite conclusion. Results: Ten eligible studies were finally enrolled in this meta-analysis. Lack of association between MTHFR A1298C polymorphism and AD risk was observed in five genetic models (allelic: OR = 1.17, 95% CI: 0.88-1.56; homozygous: OR = 1.15, 95% CI: 0.87-1.53; heterozygous: OR = 1.19, 95% CI: 0.76-1.86; dominant: OR = 1.23, 95% CI: 0.81-1.87; recessive: OR = 1.16, 95% CI: 0.89-1.52). The result of cumulative meta-analysis sorted by publication year was also detected a dynamic tendency of no correlation between MTHFR A1298C polymorphism and AD. Conclusion: This meta-analysis reveals that MTHFR A1298C polymorphism may not be associated with AD risk.

show abstract

Section: Authors Contributionmentioning

confidence: 99%

Lack of association between MTHFR A1298C variant and Alzheimer’s disease: evidence from a systematic review and cumulative meta-analysis

Liu¹,

Wu²,

Liu³

et al. 2017

Neurological Research

View full text Add to dashboard Buy / Rent full text

show abstract

“…and prescribes an intervention as a 'disease modifying therapy' (DMT) that targets change in the underlying disease process leading to cell death [52]. The mechanisms and determinants are many [53] and predominantly involve nutritional deficiency [54], inflammation [55], oxidative stress [56], mitochondrial dysfunction [57], impaired methylation pathways [58], impaired Aβ clearance [43], hormone imbalance [59], chronic stress [60], gut dysbiosis [61], insulin dysregulation [62], infections [40,[63][64][65][66], poor sleep [67], vascular disease [68], and toxicity [41,60,69,70], including heavy metals [71][72][73][74][75].…”

Section: The Logic Of Applying Personalised Medicine To Cognitive Decmentioning

confidence: 99%

Personalised Medicine for Dementia: Collaborative Research of Multimodal Non-pharmacological Treatment with the UK National Health Service (NHS)

Chalfont¹,

Simpson²,

Davies³

et al. 2019

obm geriatr

View full text Add to dashboard Buy / Rent full text

The dominant narrative around dementia argues that progression cannot be halted or reversed. However, evidence on multimodal non-pharmacological treatments formulated around a 'personalised medicine' approach challenges this view. This paper reviews the current evidence for dementia prevention utilising such treatments and explains the logic of applying personalised medicine. The functional medicine treatment approach to 'root cause' analysis is presented as currently practiced with patients experiencing cognitive decline. We report six case reports including in-depth practitioner evaluations, recommendations and follow-ups. We cover the various presentations of memory and concentration problems and the screening process with advanced functional testing. The case reports appear in a table, followed by 11 key points, insights and findings. To our knowledge, this is the first paper reporting practitioner case reports documenting improvements in symptoms of memory

show abstract

“…43 Other research suggests that Alzheimer's disease is caused by inhalation of biotoxins and mycotoxins from fungi which manifests as chronic inflammatory response syndrome. 44 Therefore, we shouldn't underestimate the role that fungi play in the aetiology of a diverse range of unwanted illness events.…”

Section: Other Risksmentioning

confidence: 99%

Mould in building disputes

L¹

2018

JBMOA

View full text Add to dashboard Buy / Rent full text

Background: Indoor air quality and water damaged buildings are increasingly a focus of civil litigation and public health concern. This paper reviews the science and practice of dealing with damp and mould in the built environment. The focus is on education for solicitors, barristers and arbitrators, builders and building consultants, architects, engineers and real estate personnel who have a common interest in dispute resolution within the property law space. In Australia, there is currently no consistent consensus regarding how and what to measure when buildings get wet or there are adverse health claims. Possible reasons include commercial self-interest from groups within the remediation industry and uneven response to claims from the insurance, residential and commercial tenancy or landlord and building sectors due to a lack of policy or professional conduct guidelines. Ignorance of basic biology and infection control are also salient factors. In the absence of defined expectations and thresholds for both the assessment and remediation stages, the occupant may be left inside a building that remains contaminated or where inappropriate resources have been applied or misapplied without justification or based on flawed reasoning. This could result in liability for key stakeholders or result in disproportionate allocation of funds that could create an unequal public health care response. The recent announcement of the Inquiry into Biotoxin-related Illnesses in Australia is likely to shine a spotlight on the need for objective evidence collection and analysis during all stages of decisionmaking about human exposure and remediation of fungi within diverse building structures. To illustrate, I review the AustLII database of the Victorian Civil and Administrative Tribunal between 1998-2018 for all cases about mould. Both the number and frequency of cases is trending up with a dominance of disputes within residential tenancy at 50%, followed by 31% for building. These results reveal issues concerning minimum housing standards and difficulties dealing with unexpected outcomes caused by newer building practices as well as dispute over contract terms, costs or health status. Compliance principles are suggested with reference to key citation and consensus methods or documents that can be used to improve the assessment and practical cleanup of indoor water damage.

show abstract

Inhalational Alzheimer's disease: an unrecognized—and treatable—epidemic

Cited by 28 publications

References 12 publications

Lack of association between MTHFR A1298C variant and Alzheimer’s disease: evidence from a systematic review and cumulative meta-analysis

Lack of association between MTHFR A1298C variant and Alzheimer’s disease: evidence from a systematic review and cumulative meta-analysis

Personalised Medicine for Dementia: Collaborative Research of Multimodal Non-pharmacological Treatment with the UK National Health Service (NHS)

Mould in building disputes

Contact Info

Product

Resources

About